Peng B, Ran T, Chen X, Ding J, Wang Z, Li W
J Med Chem. 2024; 67(10):7921-7934.
PMID: 38713486
PMC: 11129188.
DOI: 10.1021/acs.jmedchem.3c02315.
Chen X, Huang M, Fan D, He Y, Zhang W, Ding J
Nucleic Acids Res. 2024; 52(12):6811-6829.
PMID: 38676947
PMC: 11229315.
DOI: 10.1093/nar/gkae329.
Xie Z, Tian Y, Guo X, Xie N
Cell Oncol (Dordr). 2024; 47(5):1503-1522.
PMID: 38619752
PMC: 11466993.
DOI: 10.1007/s13402-024-00943-9.
Tiniakou I, Hsu P, Lopez-Zepeda L, Garipler G, Esteva E, Adams N
Sci Immunol. 2024; 9(94):eadi1023.
PMID: 38608038
PMC: 11182672.
DOI: 10.1126/sciimmunol.adi1023.
Huang Q, Fan D, Zheng Z, Ran T, Bai A, Xiao R
J Med Chem. 2024; 67(8):6658-6672.
PMID: 38569135
PMC: 11056977.
DOI: 10.1021/acs.jmedchem.4c00141.
Inhibition of CARM1-Mediated Methylation of ACSL4 Promotes Ferroptosis in Colorectal Cancer.
Feng S, Rao Z, Zhang J, She X, Chen Y, Wan K
Adv Sci (Weinh). 2023; 10(36):e2303484.
PMID: 37946697
PMC: 10754121.
DOI: 10.1002/advs.202303484.
The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma.
Kuang Z, Guo K, Cao Y, Jiang M, Wang C, Wu Q
Br J Cancer. 2023; 129(12):1915-1929.
PMID: 37884683
PMC: 10703862.
DOI: 10.1038/s41416-023-02464-y.
JMJD6-BRD4 complex stimulates lncRNA HOTAIR transcription by binding to the promoter region of HOTAIR and induces radioresistance in liver cancer stem cells.
Pei R, Zhao L, Ding Y, Su Z, Li D, Zhu S
J Transl Med. 2023; 21(1):752.
PMID: 37880710
PMC: 10599021.
DOI: 10.1186/s12967-023-04394-y.
UBE3B promotes breast cancer progression by antagonizing HIF-2α degradation.
Wang Y, Liu X, Wang M, Wang Y, Wang S, Jin L
Oncogene. 2023; 42(46):3394-3406.
PMID: 37783786
DOI: 10.1038/s41388-023-02842-z.
MAVI1, an endoplasmic reticulum-localized microprotein, suppresses antiviral innate immune response by targeting MAVS on mitochondrion.
Shi T, Huang Y, Li Y, Dai X, He Y, Ding J
Sci Adv. 2023; 9(35):eadg7053.
PMID: 37656786
PMC: 10854431.
DOI: 10.1126/sciadv.adg7053.
Proteome-wide Profiling of Asymmetric Dimethylated Arginine in Human Breast Tumors.
Ma M, Liu F, Miles H, Kim E, Fields L, Xu W
J Am Soc Mass Spectrom. 2023; 34(8):1692-1700.
PMID: 37463068
PMC: 10726702.
DOI: 10.1021/jasms.3c00154.
CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS.
Yi J, Wang L, Hu G, Zhang Y, Du J, Ding J
EMBO J. 2023; 42(10):e112408.
PMID: 37009655
PMC: 10183818.
DOI: 10.15252/embj.2022112408.
JMJD6 Shapes a Pro-tumor Microenvironment via ANXA1-Dependent Macrophage Polarization in Breast Cancer.
Cioni B, Ratti S, Piva A, Tripodi I, Milani M, Menichetti F
Mol Cancer Res. 2023; 21(6):614-627.
PMID: 36867680
PMC: 10233359.
DOI: 10.1158/1541-7786.MCR-22-0370.
A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
Xia L, Yuan L, Hu Y, Liu J, Hu G, Qi R
Cell Mol Immunol. 2023; 20(4):351-364.
PMID: 36864189
PMC: 9979130.
DOI: 10.1038/s41423-023-00985-3.
The SET oncoprotein promotes estrogen-induced transcription by facilitating establishment of active chromatin.
Guo C, Meza-Sosa K, Valle-Garcia D, Zhao G, Gao K, Yu L
Proc Natl Acad Sci U S A. 2023; 120(8):e2206878120.
PMID: 36791099
PMC: 9974495.
DOI: 10.1073/pnas.2206878120.
XLID syndrome gene Med12 promotes Ig isotype switching through chromatin modification and enhancer RNA regulation.
Haque F, Honjo T, Begum N
Sci Adv. 2022; 8(47):eadd1466.
PMID: 36427307
PMC: 9699684.
DOI: 10.1126/sciadv.add1466.
JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells.
Das P, Gupta A, Desai K
Front Endocrinol (Lausanne). 2022; 13:1028616.
PMID: 36419768
PMC: 9678079.
DOI: 10.3389/fendo.2022.1028616.
Hyperuricemia contributes to glucose intolerance of hepatic inflammatory macrophages and impairs the insulin signaling pathway IRS2-proteasome degradation.
Zhao H, Lu J, He F, Wang M, Yan Y, Chen B
Front Immunol. 2022; 13:931087.
PMID: 36177037
PMC: 9513153.
DOI: 10.3389/fimmu.2022.931087.
A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo.
Xiao R, Ran T, Huang Q, Hu G, Fan D, Yi J
Proc Natl Acad Sci U S A. 2022; 119(34):e2200753119.
PMID: 35969736
PMC: 9407455.
DOI: 10.1073/pnas.2200753119.
Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response.
Wang K, Yang C, Li H, Liu X, Zheng M, Xuan Z
Front Immunol. 2022; 13:859893.
PMID: 35359945
PMC: 8963961.
DOI: 10.3389/fimmu.2022.859893.